|Articles|September 23, 2022
Antibody-based drug discovery at the speed of light
Author(s)Curia
The combination of the PentaMice® platform and single B cell screening with the Beacon® system increases speed to market for monoclonal antibody antibody therapeutics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
2
Establishing Risk Assessments for AI in Bio-Manufacturing
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
5
